1374641-74-3

Upstream product

• 5750-76-5 2,4,5-trichloropyrimidine 
• 591-27-5 m-Hydroxyaniline 
• 76661-24-0 2,5-dichloro-4-(3-nitrophenoxy)pyrimidine 
• 554-84-7 meta-nitrophenol 

Downstream Products

• 1436851-28-3 C₂₈H₃₁ClN₆O₅ 
• 1436851-29-4 2-(4-(4-((4-(3-acrylamidophenoxy)-5-chloropyrimidin-2-yl)-amino)-3-methoxyphenyl)piperazin-1-yl)acetic acid 
• 1436851-31-8 C₃₆H₃₆ClN₉O₉S 
• 1436851-32-9 C₃₇H₃₈ClN₉O₉S 
• 1436851-33-0 C₄₀H₄₃ClN₁₀O₉S 
• 1436851-34-1 C₃₉H₄₀ClN₉O₉S 
• 1436851-35-2 C₃₇H₃₈ClN₉O₉S 
• 1436851-36-3 C₃₆H₃₅ClN₈O₁₀S 
• 1436851-37-4 C₃₇H₃₇ClN₈O₁₀S 
• 1436851-38-5 C₃₈H₃₉ClN₈O₁₀S 
• 1374641-75-4 N-(3-((2,5-dichloropyrimidin-4-yl)oxy)phenyl)acrylamide 
• 1436851-41-0 C₄₀H₄₃ClN₈O₁₀S 
• 1436851-40-9 C₃₈H₃₉ClN₈O₁₁S 
• 1436851-39-6 C₃₈H₃₅ClN₈O₁₀S 

Relevant academic research and scientific papers

Deuterated pyrimidine derivative with anti-cancer effect

The invention relates to a deuterated pyrimidine derivative with an anti-cancer effect, and belongs to the field of medicines. The invention aims to solve the problems that the in-vivo half-life period of an anti-cancer drug WZ4002 is too short, the blood

HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer

A series of hybrids (12a-k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula (I), wherein the variables are as defined herein.